AQST News and Press, Aquestive Therapeutics Inc. From 06/04/20

WARREN, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that due to the p...

Navidea Biopharmaceuticals (NYSEMKT: NAVB )  +161%  on positive Tc99m tilmanocept data in rheumatoid arthritis. More news on: Navidea Biopharmaceuticals, Inc., Medigus Ltd., Digirad Corporation, Stocks on the move, , Read more ...

The FDA approves Sunovion's Kynmobi (apomorphine hydrochloride) sublingual film for the treatment of OFF episodes in Parkinson's disease patients. More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

WARREN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced plans to advance it...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Aquestive Therapeutics, Inc. (HEI) Q1 2020 Earnings Conference Call May 07, 2020, 08:00 AM ET Company Participants Stephanie Carrington - Westwicke, IR Keith Kendall - CEO, President and Director John Maxwell - CFO Daniel Barber - COO Ken Marshall - CCO Conference Call Par...

WARREN, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management wil...

Image source: The Motley Fool. Aquestive Therapeutics, Inc.   (NASDAQ: AQST) Q1 2020 Earnings Call May 6, 2020 , 8:00 a.m. ET Operator Continue reading

Aquestive Therapeutics (NASDAQ: AQST ): Q1 GAAP EPS of -$0.49 misses by $0.04 . Revenue of $8.77M (-30.6% Y/Y) misses by $1.3M . Press Release More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

Continues to manufacture and deliver therapies and advance R&D efforts during COVID-19 pandemic  Expects to submit AQST-108 (epinephrine) IND by June 2020 and to commence PK trials by end of 2020 Continues to advance Libervant (diazepam) through FDA review proces...